Guidelines for Follow-up and SACT for Melanoma during COVID-19 Pandemic

Contents

Background ........................................................................................................................................... 2
Interventions to minimise and manage the impact of COVID-19......................................................... 2
SACT prioritisation ............................................................................................................................ 3
SACT melanoma – metastatic disease ............................................................................................... 3
SACT melanoma – adjuvant therapy ................................................................................................. 3
Proposals ........................................................................................................................................... 3
Metastatic disease ............................................................................................................................ 3
Adjuvant therapy .............................................................................................................................. 4
Routine imaging ............................................................................................................................... 5
Background

The worsening COVID-19 pandemic is likely to have major implications on the ability to deliver normal care for patients. This document identifies some of the strategies that can be taken to minimise the impact on melanoma patients and the healthcare system.

As the pandemic worsens, services are likely to come under pressure due to a number of potential factors including staff shortages due to illness, school closures, redeployment etc. At the same time, there will be increased competition for beds, supportive care facilities, imaging, etc to care for critically ill COVID-19 patients. These may have an impact on the ability to deliver treatment, to the supply chain (Pharmacy reconstitution, drug supply), and to care for patients with treatment related toxicity. Any of these changes could happen very quickly with little or no warning e.g. Pharmacy aseptics closure.

Targeted therapy and immunotherapy have different toxicity profiles with which clinicians are now very familiar. Targeted therapy with dabrafenib and trametinib (the UK market leader) is associated with a high risk of fever, rigors and malaise which mimic COVID-19 symptoms. While the majority of patients are normally managed symptomatically with supportive care meds, dose interruptions and reductions, and don’t require admission to hospital, the possibility of COVID-19 infection must now be considered. Patients calling for advice with fever and pyrexia should be told to stop treatment, take paracetamol and self-isolate. However, if the patients are well, they will not need to be admitted. If their symptoms promptly resolve on stopping drug they can discontinue self-isolation at 48 hrs.

Significant immune toxicity is common with combination immunotherapy, frequently leading to hospital admission requiring immune suppression and use of acute medical services including respiratory support. The same toxicities are seen for single agent PD-1 inhibitors though much less frequently. Immune suppression is likely to lead to patients being more susceptible to COVID-19 infection. Older patients and those with significant co-morbidities are more at risk of severe complications of COVID-19 infection and so minimising other potential contributory risk factors is particularly important in this patient group.

The guidance provided below is based on limited evidence and may require to be updated over time, but is intended to help melanoma specialist teams manage their service effectively during this unprecedented period.

Interventions to minimise and manage the impact of COVID-19

1. Reduce need for patients to visit the hospital i.e. reduce footfall in hospital, congregating in waiting areas, contamination of radiology machines, exposure to other patients and staff, etc.

2. Clinic lists should be screened in advance. Where possible, routine reviews should be deferred and replaced by a telephone call.

3. Review how frequently patients need to be seen in clinic and how treatments are prescribed, dispensed and administered.
4. Where possible, choose a treatment that minimises the risk of admission to hospital due to 
   risk of treatment-related toxicity.

5. Minimise treatment-related toxicity that could be confused for or worsen COVID-19 
   infection (fever, cough, breathlessness and pneumonitis) and would compete for acute 
   medical support.

6. Review requirements for routine imaging.

SACT prioritisation

The aim is to continue to deliver all appropriate treatments to those patients who require them. 
NICE and NHS England have now published a table prioritising SACT: 
https://www.nice.org.uk/guidance/ng161  A copy is to be found at the end of this document.

SACT melanoma – metastatic disease

Treatment of first line metastatic disease is considered the highest priority, given the major impact 
on long term survival, with median expected 5-year survival of approximately 50%. Single agent PD-
1 inhibitor is SACT Priority Level 2. Combination ipilimumab and nivolumab limited to patients with 
high risk features (bulky liver metastases, asymptomatic brain metastases) will also be SACT Priority 
Level 2.

Treatment of second line metastatic disease in patients with a BRAF mutation and so with an 
effective second line treatment (targeted therapy or immunotherapy) is also considered SACT 
Priority Level 2, though the outcomes are not as good as for first line.

Second line treatments in patients without a BRAF mutation and all subsequent lines of treatment 
have a poor outcome and so is a lower priority, SACT Priority Level 6.

NICE has removed the rules on treatment breaks for the duration of the COVID-19 emergency. 
Patients restarting treatment will need to have a Blueteq form completed.

SACT melanoma - adjuvant therapy

Adjuvant therapy has a major impact on risk of recurrence. The data for adjuvant immunotherapy is 
currently too immature to show an impact on overall survival, although this is very likely. Adjuvant 
therapy is considered SACT Priority Level 2, but a lower priority than first line treatment for 
metastatic disease. Adjuvant therapy is offered to patients with a wide range of prognosis and the 
absolute benefit in earlier Stage III patients is low. For these reasons, adjuvant therapy is considered 
a lower priority for resected stage IIIA and IIIB patients,

There is currently no consensus on which adjuvant treatment to offer patients with a BRAF 
mutation. This choice should now be informed by the risk of toxicity requiring immunosuppression 
or respiratory support.

Proposals

Metastatic disease

1. First line metastatic disease is the highest priority for treatment. (Priority Level 2)
2. Second line metastatic disease in patients with a BRAF mutation is also considered a high priority. (Priority Level 2)

3. Second line treatment in patients without a BRAF mutation and all subsequent lines of treatment have a poor outcome and so are a lower priority. (Priority Level 6)

4. For patients starting immunotherapy, the majority should start single agent PD-1 inhibitor. Consideration should be given to choosing 6-weekly pembrolizumab with a telephone call at 2-3 weeks.

5. For those patients with much higher risk disease e.g. bulky liver metastases, asymptomatic brain metastases, combination immunotherapy is still appropriate. (Priority Level 2) Consider home administration where possible and appropriate.

6. For patients requiring BRAF targeted therapy, consideration should be given to choosing encorafenib and binimetinib because of the lower chance of symptoms that mimic COVID-19 infection.

7. Metastatic disease - treatment frequency and supervision
   - Immunotherapy: 1 cycle break is acceptable in patients on treatment for >3/12. Patients require blood tests at missed cycle time-point and telephone review
   - Targeted therapy: aim for continuous treatment; patients stable on treatment beyond 4 months can safely be dispensed 8 weeks of drug without blood tests in between

**Adjuvant therapy**

8. Adjuvant therapy is considered a lower priority than first line metastatic disease but still Priority Level 2.

9. Patients with a BRAF mutation should be offered adjuvant dabrafenib and trametinib.

10. Patients who are BRAF WT should be offered 6-weekly adjuvant pembrolizumab.

11. Consider limiting adjuvant therapy to patients with the highest risk disease (stage IIIC and IIID)

12. Immunotherapy
   - If necessary, interrupt treatment for 1 cycle length (4-6 weeks) in patients who have had at least 3/12 treatment. Require blood tests at missed cycle time-point and telephone review.

13. Targeted therapy
   - Dispense 2/12 at a time for patients who have been established on treatment for four months or more. Patients do not require blood tests in between.
**Routine imaging**

14. Consider substituting CT head for MR brain to minimise number of visits, i.e. one visit for CT head, thorax, abdomen, pelvis.

15. Frequency of surveillance imaging

   - Surveillance imaging will continue as current standard. However consider extending period between follow-up scans according to local availability.

Pippa Corrie
Avinash Gupta
Mark Harries
James Larkin
Paul Lorigan
Paul Nathan
Mark Middleton
Christian Ottensmeier
Lisa Pickering

**SACT Prioritisation during COVID-19 Emergency (NICE and NHSE)**

<table>
<thead>
<tr>
<th>Priority level</th>
<th>Categorisation based on treatment intent and risk:benefit ratio of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Curative treatment with a high (more than 50%) chance of success</td>
</tr>
<tr>
<td>2</td>
<td>Curative treatment with an intermediate (15% to 50%) chance of success</td>
</tr>
<tr>
<td>3</td>
<td>Non-curative treatment with a high (more than 50%) chance of more than 1 year extension to life</td>
</tr>
<tr>
<td>4</td>
<td>Curative therapy with a low (0% to 15%) chance of success or non-curative therapy with an intermediate (15% to 50%) chance of more than 1 year extension to life</td>
</tr>
<tr>
<td></td>
<td>Non-curative therapy with a high (more than 50%) chance of palliation or temporary tumour control and less than 1 year expected extension to life</td>
</tr>
<tr>
<td>---</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>5</td>
<td>Non-curative therapy with an intermediate (15% to 50%) chance of palliation or temporary tumour control and less than 1 year expected extension to life</td>
</tr>
</tbody>
</table>